Stockreport

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Myriad Genetics, Inc.  (MYGN) 
Last myriad genetics, inc. earnings: 2/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: myriad.com/news-center/investor-information
PDF SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present [Read more]